Tina W.’s Post

Thoughts on this? >> Novartis eyed just one late-stage cancer drug from MorphoSys before upping bid for whole biotech >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #productmarketing

Thoughts on this? >> Novartis eyed just one late-stage cancer drug from MorphoSys before upping bid for whole biotech >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #pharma #productmarketing

$100 million to develop covalent biologics for oncology ! Enlaza Therapeutics just secured $100 million in Series A funding, led by J.P. Morgan Asset Management’s Private Capital division, to advance its covalent biologic platform for novel protein drugs, particularly in oncology. ⚗️Safer and more tolerable tumor penetration : Enlaza's War-LockTM technology creates biologic drugs that bind irreversibly to disease targets, enhancing efficacy and safety. By promoting covalency, it improves therapeutic performance, reduces systemic exposure, and allows sustained biologic effects with minimal dosing. Using proprietary amino acids, Enlaza engineers precise biological medicines with enhanced properties, offering a versatile solution across different protein-drug formats. 💊Investors : J.P. Morgan led the funding round, joined by existing investors like Frazier Life Sciences and new ones including Amgen and Regeneron's investment arms.

With looming patent cliffs, Big Pharma are hungry to fill their pipelines via M&A and licensing deals. Here are the top deals in January 2024:   💸 Novartis have been busy with their $250M upfront acquisition of Calypso Biotech, a $185M+ RNAi licensing deal with Argo Biopharma and up to $1.2B and $1.3B collaborations with Isomorphic Labs and Voyager Therapeutics, Inc.   💸 Eli Lilly and Company also announced a collaboration with Isomorphic, leveraging the Google/Alphabet launched company's #AlphaFold platform   💸 Johnson & Johnson make their move in the #ADC space, with a $2B acquisition of Ambrx   💸 Merck Group bolstered their #cancer #immunotherapy pipeline with a $680M acquisition of Harpoon Therapeutics   💸 Takeda paid $300M+ to license Protagonist Therapeutics' phase 3 peptide mimetic for rare #hematology disorders   💸 Sanofi acquired Inhibrx, Inc. for $1.7B for the biotech's biologic Alpha-1 Antitrypsin Deficiency (#AATD) asset   💸 GSK acquired Aiolos Bio for $1B + $400M in milestone payments for the 2 month old company's phase 2 asthma biologic

Takeda inks sweet $1.2B+ deal with Kumquat for immuno-oncology program: Takeda has offered Kumquat Biosciences the chance to make more than $1.2 billion in a new exclusive pact that centres around an immune-oncology small molecule inhibitor. After running phase 1 trial activities Kumquat can grant Takeda global licensing rights to develop and commercialise the asset. Big Pharma Takeda will then take responsibility for all development and commercialisation activities following phase 1. Subsequently a selected program can be developed as a monotherapy, combo therapy or both. Kumquat is set to make up to $130 million in near-term payments, with additional chance to grab $1.2 billion in future clinical, regulatory and commercial milestones. Share your thoughts on the collaboration: #takeda #oncology #kumquat #biosciences #licensingdeals

Great news from Orum Therapeutics, a #Korea based #biotech has been just announced. It is filing for an initial public offering (IPO) on South Korea's #Kosdaq market. https://lnkd.in/eUW_D-_2 Company is focusing it innovation pipeline on degrader-antibody conjugates (#DACs). Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD) approach uses antibodies to deliver small molecule targeted protein degrader payloads to targeted cancer cells. The TPD technology produced two most advanced products. ORM-5029 (targets #HER2) and ORM-6151 (targets #CD33 and acquired by BMS). Great news and very interesting potential for the new therapeutic modality. South Korea's biotech industry is definitively experiencing rapid growth.

Our portfolio company MediLink Therapeutics presented the clinical data of YL202 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, marking the company's inaugural clinical data disclosure since establishment. YL202 is a HER3-targeting ADC developed on Medilink Therapeutics' TMALIN platform. The company has entered into a collaboration agreement with BioNTech SE for this product. As part of the agreement, BioNTech made an initial payment of $70 million to Medilink Therapeutics, with potential total payments exceeding $1 billion, in exchange for exclusive rights for overseas development, manufacturing, and commercialization of YL202. #ASCO2024 #ADC #Biotechnology #QimingHealthcare #QimingPortfolio

#BioBDDailyHighlights Focusing on "Synthetic Lethality": Apeiron Therapeutics Sells CDK7 Inhibitor Rights July 18, 2024 | San Francisco, USA & Shanghai, China Shanghai Apeiron Therapeutics has announced an agreement with Exscientia plc (NASDAQ: EXAI) to sell 50% of its rights to the highly selective oral CDK7 inhibitor, GTAEXS617, which is currently in the ELUCIDATE Phase 1/2 clinical trials. According to the agreement, Apeiron Therapeutics will receive $30 million, with potential value exceeding $100 million. Dr. Mingxi Li, CEO of Apeiron Therapeutics, stated: “We believe Exscientia has the best resources and capabilities to develop this project. GTAEXS617 will provide more treatment options and hope for cancer patients. This transaction allows us to concentrate our resources on other high-potential 'synthetic lethality' pipelines, including the upcoming clinical MTA/PRMT5 inhibitor, GTA182.” #BIOCHINA2025 Partnering Tickets Pre-Sale Now Open Purchase your meeting tickets before the end of Q3 2024 to enjoy exclusive discounts off the original price.  Whether you represent a pharmaceutical company, biotech firm, or upstream supplier, etc We invite you to freely submit your project information. Free Registration https://lnkd.in/dbCdyVW9 Our commitment lies in facilitating tailored resource connections for your needs. 🔗💼

Innovating Cancer Treatment: Merck KGaA's $740M Collaboration 🚀 Merck KGaA partners with C4 Therapeutics, investing $16M upfront to harness cutting-edge protein degradation technology for cancer drug development. A leap towards groundbreaking treatments. #Innovation #CancerResearch #Pharmaceuticals #Biotech #DrugDevelopment #Healthcare #Oncology #ProteinDegradation #MerckKGaA #C4Therapeutics #Partnership #MedicalScience #ResearchAndDevelopment #CancerTherapy #LifeSciences #StrategicInvestment For more insights, check the full story: https://lnkd.in/gvVj-HSH

Recent Developments in Pharma 🌐🔬 1. SMS PHARMACEUTICALS LIMITED and Sri Avantika Contractors (I) Limited invest $200M in a cutting-edge pharmaceutical park in Vietnam, aiming to attract $4-5 billion in future investments. 🏭🌐 2. Sanofi and Vir Biotechnology, Inc. partner to develop innovative masked T-cell engagers (TCEs) for treating cancer. 🤝🔬 3. Prelude Therapeutics collaborates with Merck to explore cancer treatment interactions with Merck’s immunotherapy, focusing on innovative oncology solutions. 🌿🧬 4. Regeneron reports a significant surge in Q2 sales, driven by strong demand for its key products. 📈💊 Stay informed with Pharma Now! Share your thoughts on these updates in the comments below! 💬✨ #PharmaNow #PharmaNews #HealthcareInnovation #GlobalPharma #Investments #Collaborations #SalesSurge #DrugDevelopment